How We Invest

13F FILER • DANIEL SCHNEEBERGER

ADAR1 Capital Management

Daniel Schneeberger — ADAR1 Capital Management, LLC

No writing by this manager has been read and indexed yet, so this page carries the filings only. Holdings come straight from the Form 13F-HR on EDGAR.

277

Positions

$2.2B

Reported Value

40.8%

In Top 10

—

Claims Indexed

Largest reported positions

ADAR1 CAPITAL MANAGEMENT, LLC • CIK 0001940272 • 2026-06-30 • FILED 2026-08-14

WHAT CHANGED THIS QUARTER

In its Q2 2026 13F, filed Aug 14, 2026, ADAR1 Capital Management reported 277 positions worth $2.1B in US-listed stock. The largest stock position is Abivax Sa at 11.0% of the reported book, and the ten largest lines of any type make up 40.8% of it.

It opened 46 new positions, the largest stock position being Editas Medicine Inc ($28.8M), and exited 79, the largest stock exits being Terns Pharmaceuticals Inc ($48.2M last quarter), Beam Therapeutics Inc ($34.5M last quarter) and Scholar Rock Hldg Corp ($20.0M last quarter).

Among positions it already held, the biggest increases by share count were Praxis Precision Medicines I (+4850%), Rallybio Corp (+4411%) and Enanta Pharmaceuticals Inc (+2518%), and the biggest cuts were Denali Therapeutics Inc (−45%), Rhythm Pharmaceuticals Inc (−36%) and Revolution Medicines Inc (−35%).

Largest reported positions, quarter ended 2026-06-30
IssuerValueWeightShares QoQ
ABIVAX SA$240.5M11.0%+30%
PROTAGONIST THERAPEUTICS INC$117.8M5.4%-3%
ROIVANT SCIENCES LTD$111.7M5.1%-4%
STATE STR SPDR S&P 500 ETF T$96.4M4.4%+70%
IMMUNOVANT INC$89.8M4.1%-13%
ZAI LAB LTD$64.0M2.9%+136%
AGIOS PHARMACEUTICALS INC$47.8M2.2%+816%
CRINETICS PHARMACEUTICALS IN$45.7M2.1%+7%
EA SERIES TRUST$39.5M1.8%—
CYTOKINETICS INC$39.0M1.8%-28%
SEPTERNA INC$31.5M1.4%-14%
ANTERIS TECHNOLOGIES GLOBAL$31.0M1.4%-17%
EDITAS MEDICINE INC$28.8M1.3%New
DENALI THERAPEUTICS INC$26.5M1.2%-45%
SPYRE THERAPEUTICS INC$25.2M1.1%-16%
VIR BIOTECHNOLOGY INC$25.0M1.1%-11%
PRAXIS PRECISION MEDICINES I$24.9M1.1%+4850%
INSMED INC$24.4M1.1%+546%
CELLDEX THERAPEUTICS INC NEW$23.1M1.1%+45%
VIKING THERAPEUTICS INC$22.4M1.0%+152%

20 of 277 positions. 2.6% of reported value is options, where the figure is the notional value of the underlying rather than money spent. $15.6M of the reported value is Section 13(f) debt — convertible notes and the like — which the form covers alongside equities. A 13F covers long US-listed positions at a quarter end only — no shorts, leverage, cash, ordinary bonds or private holdings — and is 45 days old on publication.

NEW POSITIONS

  • Editas Medicine Inc$28.8M · 1.3%

EXITS

  • Terns Pharmaceuticals Inc$48.2M last quarter
  • Beam Therapeutics Inc$34.5M last quarter
  • Scholar Rock Hldg Corp$20.0M last quarter
  • Vertex Pharmaceuticals Inc$6.7M last quarter
  • Viridian Therapeutics Inc$6.0M last quarter

QUESTIONS PEOPLE ASK

What are ADAR1 Capital Management's largest holdings?

OPEN
As of Jun 30, 2026, the three largest stock positions are Abivax Sa (11.0%), Protagonist Therapeutics Inc (5.4%) and Roivant Sciences Ltd (5.1%), together 21.5% of the reported book.

How big is ADAR1 Capital Management's 13F portfolio?

OPEN
The Q2 2026 13F, filed Aug 14, 2026, reports 277 positions worth $2.2B. The ten largest make up 40.8% of it. 2.6% of that value is options, reported at the notional value of the underlying rather than money spent.

What did ADAR1 Capital Management buy and sell in Q2 2026?

OPEN
It opened 46 new positions, the largest stock position being Editas Medicine Inc ($28.8M), and exited 79, the largest stock exits being Terns Pharmaceuticals Inc ($48.2M last quarter), Beam Therapeutics Inc ($34.5M last quarter) and Scholar Rock Hldg Corp ($20.0M last quarter). Among positions it already held, the biggest increases by share count were Praxis Precision Medicines I (+4850%), Rallybio Corp (+4411%) and Enanta Pharmaceuticals Inc (+2518%), and the biggest cuts were Denali Therapeutics Inc (−45%), Rhythm Pharmaceuticals Inc (−36%) and Revolution Medicines Inc (−35%).

When is ADAR1 Capital Management's next 13F due?

OPEN
The Q3 2026 13F is due Nov 16, 2026. Forty-five days after the quarter ends is November 14, 2026 (Saturday), so the deadline moves to the next business day. Daniel Schneeberger's filing usually lands close to the deadline.

Filers with overlapping books